JP4009642B2 - 肥満改善用組成物 - Google Patents
肥満改善用組成物 Download PDFInfo
- Publication number
- JP4009642B2 JP4009642B2 JP2004569954A JP2004569954A JP4009642B2 JP 4009642 B2 JP4009642 B2 JP 4009642B2 JP 2004569954 A JP2004569954 A JP 2004569954A JP 2004569954 A JP2004569954 A JP 2004569954A JP 4009642 B2 JP4009642 B2 JP 4009642B2
- Authority
- JP
- Japan
- Prior art keywords
- carnitine
- genistein
- obesity
- composition
- fat diet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000008589 Obesity Diseases 0.000 title claims description 30
- 235000020824 obesity Nutrition 0.000 title claims description 28
- 239000000203 mixture Substances 0.000 title claims description 18
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 49
- 235000006539 genistein Nutrition 0.000 claims description 45
- 229940045109 genistein Drugs 0.000 claims description 45
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 45
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 45
- 230000014509 gene expression Effects 0.000 claims description 18
- 239000003826 tablet Substances 0.000 claims description 5
- 239000007901 soft capsule Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 2
- 101150073133 Cpt1a gene Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 235000009200 high fat diet Nutrition 0.000 description 36
- 230000000694 effects Effects 0.000 description 21
- 235000014113 dietary fatty acids Nutrition 0.000 description 19
- 229930195729 fatty acid Natural products 0.000 description 19
- 239000000194 fatty acid Substances 0.000 description 19
- 150000004665 fatty acids Chemical class 0.000 description 18
- 235000019197 fats Nutrition 0.000 description 16
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 14
- 235000005911 diet Nutrition 0.000 description 14
- 230000037213 diet Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 210000000577 adipose tissue Anatomy 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- 210000001789 adipocyte Anatomy 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 229960004203 carnitine Drugs 0.000 description 7
- 235000007240 daidzein Nutrition 0.000 description 7
- 210000003470 mitochondria Anatomy 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 201000010063 epididymitis Diseases 0.000 description 6
- 235000008466 glycitein Nutrition 0.000 description 6
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 description 6
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 description 6
- 210000001700 mitochondrial membrane Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 5
- 235000008696 isoflavones Nutrition 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000004133 fatty acid degradation Effects 0.000 description 4
- 230000004130 lipolysis Effects 0.000 description 4
- 150000004668 long chain fatty acids Chemical class 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- -1 Fatty acyl-CoA esters Chemical class 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 101000755720 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) Palmitoyltransferase akr1 Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 235000013736 caramel Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000002366 lipolytic effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102000005870 Coenzyme A Ligases Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 101710183280 Topoisomerase Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002185 fatty acyl-CoAs Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 235000013310 margarine Nutrition 0.000 description 2
- 239000003264 margarine Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000003687 soy isoflavones Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 101710147349 Carnitine transporter Proteins 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 150000002187 fatty acyl carnitines Chemical class 0.000 description 1
- 125000001924 fatty-acyl group Chemical group 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- NJTGANWAUPEOAX-UHFFFAOYSA-N molport-023-220-454 Chemical compound OCC(O)CO.OCC(O)CO NJTGANWAUPEOAX-UHFFFAOYSA-N 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
McCarty, Medical Hypotheses 57(3), 324-336, 2001
肥満は、エネルギーの摂取と消費のアンバランス、新陳代謝の低下による脂肪分解酵素の内分泌の低下、レプチン(leptin; 脂肪分解酵素の一種)分泌の低下、体脂肪の燃焼に関与するアドレナリン受容体の変異、遺伝的体質などが原因で、過剰な脂肪が体内に蓄積されることによって発生する。
SD雄ラットの精巣上体脂肪組織(epididymal adipose tissue)を分離してはさみで細かく切り、それに0.1%のコラゲナーゼ(フェノールレッド不含のDMEM)を加えて37℃で2時間培養した後、ろ過し、脂肪細胞(adipocyte)を採取した。
SD雄ラットの脂肪細胞における中性脂肪分解の促進効能を評価するために、上記の参考例の方法で採取した脂肪細胞を用いて実験を行なった。対照群は、本発明の組成物(実験物質)を添加せず、培地のみを使って培養したもので、実験群には、ゲニステインとL-カルニチンまたはその片方のみをそれぞれ10μmolずつ添加した。結果は、対照群を100%とし換算して示した。脂肪分解の度合いは、脂肪細胞から培地に分離されたグリセロール(glycerol)の濃度を測定し判断した。
この実験は、本発明の組成物が高脂肪食餌による肥満動物の脂質代謝に及ぼす影響を調査するためのもので、実験ではSprague-Dawley系の雄ラット(白)を用いた。高脂肪食餌による肥満において、ゲニステイン、ダイゼイン、グリシテインがどのような影響を及ぼすかを調べるため、一週間くらい慣れさせた生後6週のラットを各実験群に12匹ずつ配置した。実験群は、(1)正常脂肪食餌グループ;(2)高脂肪食餌グループ;(3)高脂肪食餌+ゲニステイン(0.2%)のグループ;(4)高脂肪食餌+L-カルニチン(0.2%)のグループ;(5)高脂肪食餌+ゲニステイン(0.2%)+L-カルニチン(0.2%)のグループ;(6)高脂肪食餌+ダイゼイン(0.2%)のグループ;(7)高脂肪食餌+ダイゼイン(0.2%)+L-カルニチン(0.2%)のグループ;(8)高脂肪食餌+グリシテイン(0.2%)のグループ;(9)高脂肪食餌+グリシテイン(0.2%)+L-カルニチン(0.2%)のグループに分け、8週間食餌を与える。実験に使う食餌は、AIN-93G精製飼料を基本とし、高脂肪食餌は脂肪が総熱量の36%(総食餌の18%)、正常食餌は脂肪が総熱量の17%(総食餌の7%)になるように調製した。この実験例2で用いた動物食餌の組成(g/kg diet)を表1に示す。
正常脂肪食餌、高脂肪食餌、高脂肪食餌+ゲニステイン(0.2%)、高脂肪食餌+L-カルニチン(0.2%)、高脂肪食餌+ゲニステイン(0.2%)+L-カルニチン(0.2%)、高脂肪食餌+ダイゼイン(0.2%)、高脂肪食餌+ダイゼイン(0.2%)+L-カルニチン(0.2%)、高脂肪食餌+グリシテイン(0.2%)、高脂肪食餌+グリシテイン(0.2%)+L-カルニチン(0.2%)の各グループの8週間にわたる実験が終わった後、ラットの精巣上体脂肪組織(epididymal adipose tissue)を摘出した。摘出された精巣上体脂肪組織を生理食塩水で洗った後、ろ過紙の上で軽く水分を取り、重さを量った。結果を表3に示す。
8週間の食餌が終わった後、高脂肪食餌、高脂肪食餌+ゲニステイン(0.2%)、高脂肪食餌+ゲニステイン(0.2%)+L-カルニチン(0.2%)、高脂肪食餌+ゲニステイン(0.4%)の4つのグループを対象に、ラットの肝臓を摘出した。まず肝組織を均質に整え、フェノールとグア二ジン・イソチオシアネート(guanidine isothiocyanate)の混合液トリゾル(TRIZOL、 Life Technologies社、 grand Island、 NY、 USA)を用いてRNAを抽出した。このようにして得られたRNAから、CPT-1 mRNAの発現の度合いをノーザンブロット(Northern blot)で測定し、これを濃度計測(densitometry)したものを図2及び図3に示した。
ゲニステイン80mg、大豆油180mg、パーム油2mg、植物油8mg、黄蝋4mg、レシチン6mgを混合し、それを通常の方法でカプセルに詰めて軟カプセルを製造した。
ゲニステイン74mg、L-カルニチン120mg、ガラクトオリゴ糖20mg、乳糖60mg、麦芽糖140mgを混合し、それを流動層乾燥機で顆粒状にした後、シュガーエステル6mgを加えて、パッチングで錠剤に加工した。錠剤の最終重量は600mgにした。
ゲニステイン80mg、L-カルニチン120mg、無水結晶ブドウ糖250mg、澱粉550mgを混合し、それを流動層造粒機で顆粒状にした後、薬包に詰めた。内容物の最終重量は1gにした。
ゲニステイン80mg、L-カルニチン120mg、ブドウ糖10g、クエン酸0.6g、液状オリゴ糖25gを混合したものに精製水300mlを加えて、200mlずつ瓶に詰めた。その後、130℃で4〜5秒間殺菌した。
ゲニステイン80mg、L-カルニチン120mg、コーンシロップ1.8g、脱脂牛乳0.5g、大豆レシチン0.5g、バーター0.6g、植物油0.4g、砂糖1.4g、マーガリン0.58g、食塩20mgを混合してキャラメルに加工した。内容物の最終重量は6gにした。
ゲニステイン80mg、L-カルニチン120mg、澱粉20g、小麦粉9g、水あめ11g、麦芽糖11mg、マーガリン6g、食塩30mg、クエン酸30mg、炭酸ナトリウム140mg、シュガーエステル(sugar ester)2gを混合してバーの形に加工した。内容物の最終重量は60gにした。
Claims (3)
- L-カルニチンとゲニステインとが混合された有効成分を全体組成物の総重量に対して20〜50重量%含有することを特徴とする、CPT-1遺伝子の発現を増加させる経口用肥満改善用医薬組成物。
- 有効成分としてL-カルニチンとL-カルニチンの含量より少ないゲニステインとが混合されていることを特徴とする、請求項1に記載のCPT-1遺伝子の発現を増加させる経口用肥満改善用医薬組成物。
- 組成物の剤型が錠剤、カプセル剤、軟カプセル剤、丸剤、又は顆粒剤であることを特徴とする、請求項1又は2に記載のCPT-1遺伝子の発現を増加させる経口用肥満改善用医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-0018559A KR100520408B1 (ko) | 2003-03-25 | 2003-03-25 | 비만개선용 조성물 |
PCT/KR2003/002202 WO2004084885A1 (en) | 2003-03-25 | 2003-10-21 | Compositions for the improvement of obesity |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006514674A JP2006514674A (ja) | 2006-05-11 |
JP4009642B2 true JP4009642B2 (ja) | 2007-11-21 |
Family
ID=36539276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004569954A Expired - Lifetime JP4009642B2 (ja) | 2003-03-25 | 2003-10-21 | 肥満改善用組成物 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20050130912A1 (ja) |
JP (1) | JP4009642B2 (ja) |
KR (1) | KR100520408B1 (ja) |
CN (1) | CN1758906B (ja) |
AU (1) | AU2003273083A1 (ja) |
WO (1) | WO2004084885A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004093865A1 (en) * | 2003-04-24 | 2004-11-04 | Amorepacific Corporation | Composition for slimming |
CA2559974C (en) * | 2004-03-17 | 2012-08-14 | Nestec S.A. | Compositions and methods for reducing or preventing obesity |
DE102004060314A1 (de) * | 2004-12-08 | 2006-08-31 | Beiersdorf Ag | Wirkstoffkombinationen aus einem oder mehreren Isoflavonoiden und Carnitin und/oder einem oder mehreren Acyl-Carnitinen |
CN101119720B (zh) | 2005-02-15 | 2013-01-23 | 帝斯曼知识产权资产管理有限公司 | 包含多糖的组合物 |
JP2009514824A (ja) * | 2005-11-02 | 2009-04-09 | ネステク ソシエテ アノニム | 雄の哺乳動物における体脂肪の蓄積を低減するためのイソフラボン組成物及びその使用方法 |
JP5066706B2 (ja) * | 2006-02-28 | 2012-11-07 | 国立大学法人徳島大学 | 抗肥満剤のスクリーニング方法 |
GB0606864D0 (en) * | 2006-04-05 | 2006-05-17 | Univ Nottingham | Increades fatty acid oxidation |
JP5019789B2 (ja) * | 2006-05-31 | 2012-09-05 | 常盤薬品工業株式会社 | 固形製剤 |
KR101069502B1 (ko) * | 2006-10-31 | 2011-09-30 | (주)아모레퍼시픽 | 비만 및 당뇨병 개선용 경구용 조성물 |
US7767248B2 (en) * | 2007-02-02 | 2010-08-03 | Overly Iii Harry J | Soft chew confectionary with high fiber and sugar content and method for making same |
JP5121308B2 (ja) * | 2007-05-28 | 2013-01-16 | ハウスウェルネスフーズ株式会社 | メタボリックシンドロームの予防、改善または治療組成物 |
US20090011079A1 (en) * | 2007-07-02 | 2009-01-08 | Bestsweet, Inc. | Hard Coated Confectionary Having A Consumable Soft Chewing Core With An Active And Method For Making Same |
AU2009282482B2 (en) * | 2008-08-15 | 2015-11-26 | Société des Produits Nestlé S.A. | Methods for enhancing energy metabolism |
KR20100025299A (ko) * | 2008-08-27 | 2010-03-09 | 씨제이제일제당 (주) | 비만 또는 당뇨병의 예방 또는 개선용 조성물 |
EP2819752A4 (en) * | 2012-02-29 | 2016-03-09 | Avon Prod Inc | USE OF MODULATORS OF CPT-1 AND ASSOCIATED COMPOSITIONS |
GB201304112D0 (en) * | 2013-03-07 | 2013-04-24 | Univ Nottingham | Modulation of energy expenditure |
EP3900720A1 (en) * | 2020-04-22 | 2021-10-27 | Sunnutrapharma S.r.l. | Composition based on genistein for the treatment of obesity |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3810994A (en) * | 1972-06-01 | 1974-05-14 | Ethyl Corp | Method and composition for treating obesity |
IT1276253B1 (it) * | 1995-12-15 | 1997-10-27 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi |
JP3578566B2 (ja) * | 1996-08-23 | 2004-10-20 | 伊藤ハム株式会社 | 肥満改善及びダイエット食用素材並びにそれを用いたダイエット用食品 |
US5855892A (en) * | 1997-09-19 | 1999-01-05 | Potter; Susan M. | Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease |
JPH11228430A (ja) * | 1998-02-20 | 1999-08-24 | Asahi Breweries Ltd | 脂肪分解促進剤 |
WO1999065335A1 (en) * | 1998-06-19 | 1999-12-23 | Beth Israel Deaconess Medical Center | Dietary supplement for individuals under stress |
IT1299191B1 (it) * | 1998-06-23 | 2000-02-29 | Sigma Tau Healthscience Spa | Composizione atta a prevenire e trattare l'osteoporosi e le alterazioni legate alla menopausa |
ATE549939T1 (de) * | 1999-02-24 | 2012-04-15 | Iams Company | Diätzusammensetzungen und verfahren |
WO2001074345A2 (en) * | 2000-03-31 | 2001-10-11 | Jonathan Ingram | Isoflavones for treatment of obesity |
KR20020060577A (ko) * | 2000-07-07 | 2002-07-18 | 아키라 이가키 | 비만 억제제 |
WO2004093865A1 (en) * | 2003-04-24 | 2004-11-04 | Amorepacific Corporation | Composition for slimming |
-
2003
- 2003-03-25 KR KR10-2003-0018559A patent/KR100520408B1/ko active IP Right Grant
- 2003-10-21 WO PCT/KR2003/002202 patent/WO2004084885A1/en active Application Filing
- 2003-10-21 AU AU2003273083A patent/AU2003273083A1/en not_active Abandoned
- 2003-10-21 CN CN200380110196XA patent/CN1758906B/zh not_active Expired - Lifetime
- 2003-10-21 JP JP2004569954A patent/JP4009642B2/ja not_active Expired - Lifetime
- 2003-10-21 US US10/507,779 patent/US20050130912A1/en not_active Abandoned
-
2008
- 2008-03-07 US US12/044,040 patent/US20080181940A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1758906B (zh) | 2010-04-28 |
US20080181940A1 (en) | 2008-07-31 |
JP2006514674A (ja) | 2006-05-11 |
US20050130912A1 (en) | 2005-06-16 |
WO2004084885A1 (en) | 2004-10-07 |
KR20040083874A (ko) | 2004-10-06 |
CN1758906A (zh) | 2006-04-12 |
AU2003273083A1 (en) | 2004-10-18 |
KR100520408B1 (ko) | 2005-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4009642B2 (ja) | 肥満改善用組成物 | |
AU2009206753B2 (en) | Protopanaxadiol-type ginsenoside compositions and uses thereof | |
JP4669920B2 (ja) | 血糖上昇抑制且つ血圧上昇抑制作用を有する機能性素材 | |
KR20080105470A (ko) | 인삼 열매 추출물을 함유하는 비만 예방 및 개선용 식품조성물 | |
WO2007119837A1 (ja) | リパーゼ阻害剤 | |
Hemat | Principles of orthomolecularism | |
WO2005074961A1 (ja) | 体脂肪調整剤 | |
JP3749978B2 (ja) | 抗骨粗鬆症作用を発揮する骨形成増進組成物 | |
JP2008533113A (ja) | 体重増調整組成物の製造におけるタマネギ抽出物の使用 | |
KR100304312B1 (ko) | 아연이보충된전립선추출물 | |
KR100522253B1 (ko) | 비만개선용 식품 조성물 | |
AU2016210540B2 (en) | Chlorophyll composition | |
WO2022013581A1 (en) | Nutritional supplement, suitable for oral administration, comprising dihydromyricetin, choline and one or more vitamins with antioxidant activity, for use in the maintenance of normal liver function | |
KR101139070B1 (ko) | 지방간 개선용 조성물 | |
JP2021078397A (ja) | 脂質減少促進剤 | |
JP4896531B2 (ja) | 血中CoQ10量を増加させる医薬組成物 | |
KR20170026240A (ko) | 간 기능 개선용 건강기능식품 조성물 | |
JPH119221A (ja) | 抗骨粗鬆症組成物 | |
KR20050064127A (ko) | 식이섬유를 함유하는 슬리밍 식품 조성물 | |
WO2001087315A1 (en) | Treatment or prevention of metabolic bone disorder | |
CN111011850A (zh) | 一种含有植物甾醇的组合物的用途 | |
JP2011246434A (ja) | フユボダイジュ花のエタノール抽出物を有効成分とする血中グルコース低下剤、内臓脂肪蓄積抑制剤、tg低下剤、糞中脂肪排泄促進剤 | |
US20080161385A1 (en) | Composition Inhibiting Sex Hormone-Binding Globulin | |
Braverman | The Healing Nutrients Within (Volume 1 of 2)(EasyRead Comfort Edition) | |
JP2006124340A (ja) | ニンニク卵黄を含有する高脂血症の予防及び/又は治療用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060216 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060518 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060613 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061003 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060928 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20061030 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070717 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070724 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070814 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070903 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100907 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4009642 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110907 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120907 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130907 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |